Dr. Reisa Sperling with Brigham and Women’s Hospital is one of the nation’s top experts when it comes to Alzheimer’s disease. And it is deeply personal for her as the neurodegenerative condition hit her grandfather while she was in medical school and three years ago, she lost her father to the disease. Serving as a principal investigator in a clinical trial called “A4,” she commits to stopping this disease that robs humans of memory itself.
Sponsored by Eli Lilly and the Alzheimer’s Therapeutic Research Institute, the A4 study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains who may be at risk for memory loss and cognitive decline due to Alzheimer's disease. The sponsors and investigators, thanks to participants, will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia with the aim of slowing memory and cognitive decline. The A4 study also assesses whether anti-amyloid treatment can delay the progression of Alzheimer’s disease related brain injury on imaging and other biomarkers.
As WMC 5 Action News reported, the ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).